Lannett Co Inc (LCI) 32.82 $LCI
Lannett Receives FDA Approval for Diazepam Oral Solution (Concentrate), 5 mg/mL
Business Wire - Tue Apr 15, 6:54AM CDT
Lannett Company, Inc. (NYSE:LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Diazepam Oral Solution (Concentrate), 5 mg/mL, a Schedule C-IV controlled drug. Diazepam Oral Solution (Concentrate), 5 mg/mL, is therapeutically equivalent to the reference listed drug, Diazepam Intensol Oral Solution (Concentrate), 5 mg/mL, of Roxane Laboratories, Inc.
Pacira and Patheon Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:10PM CDT
Pacira has signed a strategic co-production partnership deal with Patheon.
Additional Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:20PM CDT
Pacira announced additional phase III data on its lead product, Exparel.
Merck KGaA and Auxogyn Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 4:00PM CDT
Merck KGaA entered into an exclusive license agreement with Auxogyn, Inc. for the Early Embryo Viability Assessment (Eeva) test.
Merck KGaA, Pfizer and Broad Institute Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:10PM CDT
Recently, Merck KGaA's biopharmaceutical division, Merck Serono, entered into a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, MA.
Pacira Up as Exparel Site Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:00PM CDT
Pacira Pharma's shares gained 10.7% after the FDA approved of an additional manufacturing suite (Suite C) for Exparel.
Concert Pharmaceuticals (CNCE) Catches Eye: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:25AM CDT
Concert Pharmaceuticals was a big mover last session, with shares rising over 9% on the day.
Business Plans, Clinical Trial Results, Meetings, Conferences, and Sponsorships - Analyst Notes on Baxter, Halozyme, WellCare, PDL BioPharma, and Lannett
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Halozyme Therapeutics, Inc. (NASDAQ: HALO), WellCare Health Plans, Inc. (NYSE: WCG), PDL BioPharma, Inc. (NASDAQ: PDLI), and Lannett Company, Inc. (NYSE: LCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Abbott's Supera Stent Approved in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:50PM CDT
Abbott received a boost for its vascular portfolio when the FDA approved its Supera Peripheral Stent System for the treatment of people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD).
Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris
Dr. Reddy's Launches Generic Caduet - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:07PM CDT
Dr. Reddy's announced the launch of its therapeutic equivalent generic version of Pfizer's Caduet
Endocyte (ECYT) in Focus: Stock Tumbles 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 7:47AM CDT
Endocyte, Inc. (ECYT) saw a big move last session, reversing the recent trend for ECYT as the stock is now up more than 75.0% in the past one-month time frame.
Lannett to Present at the 13th Annual Needham Healthcare Conference on April 8th
Business Wire - Thu Mar 27, 6:56AM CDT
Lannett Company, Inc. (NYSE: LCI) today announced that the company's president and chief executive officer, Arthur Bedrosian and chief financial officer, Martin Galvan, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 5 p.m. ET at The Westin Grand Central Hotel, in New York.
Update on Eagle Pharma's Ryanodex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 11:00AM CDT
The FDA will review the NDA on Ryanodex on a priority basis.
Analytical Notes on Health Care Equities -- Research on TherapeuticsMD, China Pharma Holdings, Pacira Pharma, and Lannett
PR Newswire - Wed Mar 26, 10:15AM CDT
The trading session on Tuesday, March 25, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,367.88, up 0.56% and the NASDAQ Composite closed at 4,234.27, up 0.19%. The S&P 500 finished the session 0.44% higher at 1,865.62. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day 0.83% higher at 671.69, while the same has advanced 5.27% in the last three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), China Pharma Holdings Inc. (NYSE MKT: CPHI), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Lannett Co. Inc. (NYSE: LCI). Free technical research on TXMD, CPHI, PCRX, and LCI can be downloaded upon signing up at:
Today's Dead Cat Bounce Stock Is Lannett Company (LCI)
at The Street - Tue Mar 25, 8:46AM CDT
Trade-Ideas LLC identified Lannett Company (LCI) as a "dead cat bounce" (down big yesterday but up big today) candidate
MEI Pharma (MEIP) Crumbles: Stock Falls by 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 7:53AM CDT
MEI Pharma, Inc. (MEIP) saw a big move last session, reversing the recent trend for MEIP as the stock is now up around 17.2% in the past one-month time frame.
Pipeline Update from Alcobra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 11:10AM CDT
Alcobra enrolled the first patient in a randomized, placebo-controlled phase III study on metadoxine extended release (MDX) for attention deficit hyperactivity disorder (ADHD).
Flamel (FLML) Catches Eye: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:25AM CDT
Flamel Technologies was a big mover last session, with shares rising nearly 11% on the day.
Catalyst Pharmaceutical Partners (CPRX) in Focus: Stock Moves 6.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:21AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Lannett Receives FDA Approval for Diazepam Oral Solution (Concentrate), 5 mg/mL
Business Wire - Tue Apr 15, 6:54AM CDT
Lannett Company, Inc. (NYSE:LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Diazepam Oral Solution (Concentrate), 5 mg/mL, a Schedule C-IV controlled drug. Diazepam Oral Solution (Concentrate), 5 mg/mL, is therapeutically equivalent to the reference listed drug, Diazepam Intensol Oral Solution (Concentrate), 5 mg/mL, of Roxane Laboratories, Inc.
Pacira and Patheon Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:10PM CDT
Pacira has signed a strategic co-production partnership deal with Patheon.
Additional Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:20PM CDT
Pacira announced additional phase III data on its lead product, Exparel.
Merck KGaA and Auxogyn Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 4:00PM CDT
Merck KGaA entered into an exclusive license agreement with Auxogyn, Inc. for the Early Embryo Viability Assessment (Eeva) test.
Merck KGaA, Pfizer and Broad Institute Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:10PM CDT
Recently, Merck KGaA's biopharmaceutical division, Merck Serono, entered into a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, MA.
Pacira Up as Exparel Site Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:00PM CDT
Pacira Pharma's shares gained 10.7% after the FDA approved of an additional manufacturing suite (Suite C) for Exparel.
Concert Pharmaceuticals (CNCE) Catches Eye: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:25AM CDT
Concert Pharmaceuticals was a big mover last session, with shares rising over 9% on the day.
Business Plans, Clinical Trial Results, Meetings, Conferences, and Sponsorships - Analyst Notes on Baxter, Halozyme, WellCare, PDL BioPharma, and Lannett
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Halozyme Therapeutics, Inc. (NASDAQ: HALO), WellCare Health Plans, Inc. (NYSE: WCG), PDL BioPharma, Inc. (NASDAQ: PDLI), and Lannett Company, Inc. (NYSE: LCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Abbott's Supera Stent Approved in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:50PM CDT
Abbott received a boost for its vascular portfolio when the FDA approved its Supera Peripheral Stent System for the treatment of people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD).
Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris
Dr. Reddy's Launches Generic Caduet - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:07PM CDT
Dr. Reddy's announced the launch of its therapeutic equivalent generic version of Pfizer's Caduet
Endocyte (ECYT) in Focus: Stock Tumbles 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 7:47AM CDT
Endocyte, Inc. (ECYT) saw a big move last session, reversing the recent trend for ECYT as the stock is now up more than 75.0% in the past one-month time frame.
Lannett to Present at the 13th Annual Needham Healthcare Conference on April 8th
Business Wire - Thu Mar 27, 6:56AM CDT
Lannett Company, Inc. (NYSE: LCI) today announced that the company's president and chief executive officer, Arthur Bedrosian and chief financial officer, Martin Galvan, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 5 p.m. ET at The Westin Grand Central Hotel, in New York.
Update on Eagle Pharma's Ryanodex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 11:00AM CDT
The FDA will review the NDA on Ryanodex on a priority basis.
Analytical Notes on Health Care Equities -- Research on TherapeuticsMD, China Pharma Holdings, Pacira Pharma, and Lannett
PR Newswire - Wed Mar 26, 10:15AM CDT
The trading session on Tuesday, March 25, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,367.88, up 0.56% and the NASDAQ Composite closed at 4,234.27, up 0.19%. The S&P 500 finished the session 0.44% higher at 1,865.62. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day 0.83% higher at 671.69, while the same has advanced 5.27% in the last three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), China Pharma Holdings Inc. (NYSE MKT: CPHI), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Lannett Co. Inc. (NYSE: LCI). Free technical research on TXMD, CPHI, PCRX, and LCI can be downloaded upon signing up at:
Today's Dead Cat Bounce Stock Is Lannett Company (LCI)
at The Street - Tue Mar 25, 8:46AM CDT
Trade-Ideas LLC identified Lannett Company (LCI) as a "dead cat bounce" (down big yesterday but up big today) candidate
MEI Pharma (MEIP) Crumbles: Stock Falls by 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 7:53AM CDT
MEI Pharma, Inc. (MEIP) saw a big move last session, reversing the recent trend for MEIP as the stock is now up around 17.2% in the past one-month time frame.
Pipeline Update from Alcobra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 11:10AM CDT
Alcobra enrolled the first patient in a randomized, placebo-controlled phase III study on metadoxine extended release (MDX) for attention deficit hyperactivity disorder (ADHD).
Flamel (FLML) Catches Eye: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:25AM CDT
Flamel Technologies was a big mover last session, with shares rising nearly 11% on the day.
Catalyst Pharmaceutical Partners (CPRX) in Focus: Stock Moves 6.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:21AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
